Elisa Barone
University of Pisa
14 Papers
36 Citations
Elisa Barone is an academic researcher from University of Pisa. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 7, co-authored 11 publications.
Chat about Author
Papers
Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.
Alessio Naccarati,Fabio Rosa,Veronika Vymetalkova,Elisa Barone,Katerina Jiraskova,Cornelia Di Gaetano,Jan Novotny,Miroslav Levy,Ludmila Vodickova,Federica Gemignani,Tomas Buchler,Stefano Landi,Pavel Vodicka,Barbara Pardini +13 more
TL;DR: Naccarati et al. as discussed by the authors analyzed the association of polymorphisms in predicted microRNA target sites of double-strand break (DSBs) repair genes with colorectal cancer (CRC) risk and clinical outcome.
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.
Sonia Garritano,Chiara De Santi,Roberto Silvestri,Ombretta Melaiu,Monica Cipollini,Elisa Barone,Marco Lucchi,Roberto Barale,Luciano Mutti,Federica Gemignani,Alessandra Bonotti,Rudy Foddis,Alfonso Cristaudo,Stefano Landi +13 more
TL;DR: SMRP performance as diagnostic biomarker improved by considering the genotype rs1057147, which most likely affects a binding site for miR-611, and among non-MPM volunteers, GG homozygotes have the lowest SMRP levels.
22
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines
Ombretta Melaiu,Calogerina Catalano,Chiara De Santi,Monica Cipollini,Gisella Figlioli,Lucia Pellè,Elisa Barone,Monica Evangelista,Alice Guazzelli,Laura Boldrini,Elisa Sensi,Alessandra Bonotti,Rudy Foddis,Alfonso Cristaudo,Luciano Mutti,Gabriella Fontanini,Federica Gemignani,Stefano Landi +17 more
TL;DR: This study highlights PDGFRB as target with a clear role inMPM tumorigenesis and provided a rationale to explore further the efficacy of crenolanib in MPM patients, with promising results.
Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases
Maria De Santis,Francesca Motta,Natasa Isailovic,Massimo Clementi,Elena Criscuolo,Nicola Clementi,A. Tonutti,Stefano Rodolfi,Elisa Barone,F Colapietro,Angela Ceribelli,Matteo Vecellio,Nicoletta Luciano,Giacomo Maria Guidelli,Marta Caprioli,Clara Rezk,Lorenzo Maria Canziani,Elena Azzolini,Luca Germagnoli,Nicasio Mancini,Ana Lleo,Carlo Selmi +21 more
TL;DR: Mycophenolate treatment affects the Moderna-1273 mRNA vaccine immunogenicity in a dose-dependent manner, independent of rheumatological disease and the cytotoxic activity elicited by viral peptides was also impaired.
Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.
TL;DR: The clinical implications of confirmed overexpressed genes in MPM described so far are reviewed and a group of 51 genes that resulted overexpression in more than one independent study, revealing their consistency among studies are reviewed.